Overall rank by patents
#28,722
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
Eyeyon holds 9 US patents across 6 technology areas, rank #28,722 of 50,000 tracked assignees.
Eyeyon Medical Ltd. has been granted 9 US utility patents between 2015 and 2024, placing Eyeyon Medical Ltd. at rank #28,722 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.7 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Eyeyon Medical Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Eyeyon sits between Excelitas Noblelight Gmbh (9 patents, rank #28,718) and Faultless Starch/bon AMI Company (9 patents, rank #28,726) - the closest US assignees by grant volume. The composite Innovation Score of 31.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 2 in the 2015–2019 window, a +250% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Eyeyon Medical Ltd.'s 10.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Eyeyon Medical Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Excelitas Noblelight GmbH
9 patents
Expanse Bioinformatics
9 patents
Extensive Energy Technologies Partnership
9 patents
Eyce, LLC
9 patents
F2G Ltd
9 patents
FARPOINTE DATA, INC.
9 patents
FASTREE3D SA
9 patents
FAULTLESS STARCH/BON AMI COMPANY
9 patents
Eyeyon Medical Ltd.
9 patents
What this shows Eyeyon holds 9 patents at rank #28,722, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #28,722 in granted patent volume.
Other assignees with the most granted patents in Eyeyon's primary technology class.
Eyeyon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 61% higher than 39% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 11.1% |
| 2018 | 1 | 11.1% |
| 2021 | 3 | 33.3% |
| 2023 | 2 | 22.2% |
| 2024 | 2 | 22.2% |
Top 6 of 6 technology areas
Overall rank by patents
#28,722
Across all tracked assignees
31.9 out of 100
How to use this portfolio
Eyeyon's 9 grants land it in the top 61% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.